Profile: Hospira Inc (HSP.N)
4 Aug 2015
Hospira, Inc., incorporated on September 16, 2003, provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company’s portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. The Company conducts operations across the world and is managed in three segments: the Americas, which include the United States, Canada, and Latin America; Europe, Middle East, and Africa, and Asia Pacific, which includes Asia, Japan, Australia and New Zealand. Its portfolio of products includes Specialty Injectable Pharmaceuticals, which includes generic injectables, injectables and biosimilars, Medication Management and Other Pharmaceuticals. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
Specialty Injectable Pharmaceuticals
The Company’s Specialty Injectable Pharmaceutical product (SIP) category primarily consists of generic injectable pharmaceuticals, often referred to as generics, biosimilars and pharmaceuticals. Its generic injectable pharmaceuticals are sold in therapeutic areas, including analgesia, anesthesia, anti-infectives, cardiovascular, oncology and other. In addition to generics, its SIP category includes biosimilars, which are biologic drugs that are similar to a reference biopharmaceutical product and demonstrate no clinically meaningful differences in terms of the safety, purity and potency of the product. The Company’s portfolio includes: Retacrit, a biosimilar EPO primarily for the treatment of anemia in dialysis and in certain oncology applications; Nivestim, a biosimilar filgrastim for the treatment of low white blood cells in patients who have received a chemotherapeutic agent, and Inflectra, a biosimilar infliximab for patients with autoimmune diseases, such as rheumatoid arthritis and inflammatory bowel disease. Specialty injectables included in its SIP category consist mainly of Precedex (dexmedetomidine HCl), a sedative for use in non-intubated patients requiring sedation, as well as intubated and mechanically ventilated patients in the intensive care setting and Dyloject, a nonsteroidal anti-inflammatory drug (NSAID) analgesic. Dyloject is indicated for use in adults for the management of mild to moderate pain and for the management of moderate to severe pain, alone or in combination with opioid analgesics. It offers a range of drug delivery options. Its standard drug delivery system formats include offerings in ampules and flip-top vials, which clinicians can use with standard syringes. Its sophisticated drug delivery options include Carpuject and iSecure prefilled syringes, Ansyr prefilled needleless emergency syringe systems, First Choice ready-to-use premix and the ADD-Vantage system for preparing drug solutions from prepackaged drug powders or concentrates.
The Company’s pump platform includes five infusion pumps and related administration sets, such as Plum 360 and Plum A+, LifeCare PCA, and Sapphire and SapphirePlus. The Plum 360 infusion pump is the next-generation of its Plum A+ infusion pump, builds on the Plum A+ air management and concurrent delivery features. The LifeCare PCA infusion pump is its patient-controlled analgesia device. The Sapphire infusion pump is a multi-therapy, compact, touchscreen infusion system used in ambulatory and hospital settings, and the SapphirePlus pump is a Hospira MedNet ready general-infusion device, which features technology, design and a touch screen. Sapphire and SapphirePlus are marketed and distributed through an agreement with Q Core Medical, Ltd.
The Company offers the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. Using its drug library and programmable drug dosage limits, the system can help ensure that medication is infused within hospital-defined dose guidelines and practices. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. The Hospira MedNet system is available for the Plum A+, Plum 360, LifeCare PCA and SapphirePlus devices. The Medication management product line also includes gravity administration sets and other device products, including needlestick safety products and programs to support its customers' needlestick prevention initiatives. LifeShield, CLAVE and MicroCLAVE connectors are one-piece valves that directly connect syringes filled with medications to a patient's I.V. line without the use of needles.
The Company’s Other Pharmaceuticals primarily consists of intravenous (I.V.) solutions, nutritionals and contract manufacturing services. It offers infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company’s contract manufacturing services are offered through its One2One contract manufacturing services group, which primarily provides formulation development and injectable filling and finishing services in a range of delivery systems. The Company works with its pharmaceutical and biotechnology customers to develop stable injectable forms of their drugs, and it fills and finishes those and other drugs into containers and packaging selected by the customer. The customer then sells the finished products under its own label.
The Company competes with Baxter International Inc., Becton, Dickinson and Company, Fresenius Kabi AG, Mallinckrodt plc, Mylan Inc, Par Pharmaceuticals Companies, Inc., Pfizer Inc., Sandoz, Sanofi S.A., Teva Pharmaceuticals, B. Braun Melsungen AG, CareFusion Corporation, Smiths Medical, Terumo Medical Corporation, Actavis plc, Intas Pharmaceuticals, Ltd., Janssen Pharmaceuticals, Inc., Medac GmbH and Aspen Medical.
275 N Field Dr
LAKE FOREST IL 60045-2579